1994 Volume 42 Issue Supplement4 Pages 686-690
We studied the efficacy, usefulness, and safety of biapenem (BIPM), a new injectable carbapenem antibiotic for the treatment of respiratory infections.
One patient with pneumoniae was given 300mg of BIPM by i.v. drip infusion over 60 minutes. The BIPM concentration in blood was 9.08μg/ml immediately after the drip infusion, and 1.90μg/ml after 3 hours. The maximum concentration in sputum was 0.72μg/ml which was observed at 30 minutes after the infusion, and the transfer of BIPM into the sputum was 12.6%, these findings suggesting a rapid transfer into the sputum.
BIPM in a dose of 150mg or 300mg was administered two or three times per day to a total of 18 patients including 10 with pneumonia, one with lung abscess, and one with acute exacerbation of chronic bronchitis. The remaining six patients were unevaluable or had diseases other than subjected. The patients were treated for 2 to 16 days, and the total amount of BIPM administered ranged from 1.8 to 9.0g.
Clinical response was excellent in five patients, good in five, fair in one and poor in one. The efficacy rate was 83.3%.
No side effects were observed. Abnormal laboratory findings attributable to this drug were elevations of GOT, GPT and γ-GPT in two patients and elevations of Alp and LAP in one patient.
From the results, we can conclude that BIPM is effective and useful for the treatment of respiratory infections.
